Afatinib as first-line treatment in patients with

Wolfgang  Brückl; Martin Reck; Frank Griesinger; Harald Schäfer; Cornelius Kortsik; Tobias Gaska; Justyna Rawluk; Stefan Krüger; Konrad Kokowski; Stephan Budweiser; Joachim H. Ficker; Christopher Hoffmann; Andrea Schüler; Eckart Laack

doi:10.1177/17588359211012361

Afatinib as first-line treatment in patients with

Wolfgang Brückl^* (First author), Martin Reck, Frank Griesinger, Harald Schäfer, Cornelius Kortsik, Tobias Gaska, Justyna Rawluk, Stefan Krüger, Konrad Kokowski, Stephan Budweiser, Joachim H. Ficker (Co-author), Christopher Hoffmann, Andrea Schüler, Eckart Laack

^*Corresponding author for this work

Department of Internal Medicine III, Division of Respiratory Medicine, Allergology and Sleep Medicine

Research output: Contribution to journal › Original Article (Journal) › peer-review

10 Citations (Web of Science)

Original language	English
Pages (from-to)	17588359211012361
Journal	THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
Volume	13
DOIs	https://doi.org/10.1177/17588359211012361
Publication status	Published - 2021

Keywords

REAL-WORLD
OPEN-LABEL
PHASE-III
COMPARING AFATINIB
SURVIVAL-DATA
MUTATIONS
ADENOCARCINOMA
CHEMOTHERAPY
GEFITINIB
EFFICACY

Access to Document

10.1177/17588359211012361

Cite this

@article{a35cf82b1c1147c8ac0d207aa0ee914a,

title = "Afatinib as first-line treatment in patients with ",

keywords = "REAL-WORLD, OPEN-LABEL, PHASE-III, COMPARING AFATINIB, SURVIVAL-DATA, MUTATIONS, ADENOCARCINOMA, CHEMOTHERAPY, GEFITINIB, EFFICACY",

author = "Wolfgang Br{\"u}ckl and Martin Reck and Frank Griesinger and Harald Sch{\"a}fer and Cornelius Kortsik and Tobias Gaska and Justyna Rawluk and Stefan Kr{\"u}ger and Konrad Kokowski and Stephan Budweiser and Ficker, {Joachim H.} and Christopher Hoffmann and Andrea Sch{\"u}ler and Eckart Laack",

note = "Br{\"u}ckl; Ficker: Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuremberg, Ernst-Nathan-Str.1, Nuremberg, 90419, Germany; Lehr-KH: RoMed Clin Ctr, Dept Internal Med 3, Div Pulm *** Resp Med, Rosenheim, Germany;",

year = "2021",

doi = "10.1177/17588359211012361",

language = "English",

volume = "13",

pages = "17588359211012361",

journal = "THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY",

issn = "1758-8340",

}

TY - JOUR

T1 - Afatinib as first-line treatment in patients with

AU - Brückl, Wolfgang

AU - Reck, Martin

AU - Griesinger, Frank

AU - Schäfer, Harald

AU - Kortsik, Cornelius

AU - Gaska, Tobias

AU - Rawluk, Justyna

AU - Krüger, Stefan

AU - Kokowski, Konrad

AU - Budweiser, Stephan

AU - Ficker, Joachim H.

AU - Hoffmann, Christopher

AU - Schüler, Andrea

AU - Laack, Eckart

N1 - Brückl; Ficker: Department of Respiratory Medicine, Allergology and Sleep Medicine, Paracelsus Medical University, General Hospital Nuremberg, Ernst-Nathan-Str.1, Nuremberg, 90419, Germany; Lehr-KH: RoMed Clin Ctr, Dept Internal Med 3, Div Pulm *** Resp Med, Rosenheim, Germany;

PY - 2021

Y1 - 2021

KW - REAL-WORLD

KW - OPEN-LABEL

KW - PHASE-III

KW - COMPARING AFATINIB

KW - SURVIVAL-DATA

KW - MUTATIONS

KW - ADENOCARCINOMA

KW - CHEMOTHERAPY

KW - GEFITINIB

KW - EFFICACY

U2 - 10.1177/17588359211012361

DO - 10.1177/17588359211012361

M3 - Original Article (Journal)

C2 - 33995597

SN - 1758-8340

VL - 13

SP - 17588359211012361

JO - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

JF - THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

ER -